Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Nabriva Therapeutics stock

Learn how to easily invest in Nabriva Therapeutics stock.

Nabriva Therapeutics is a biotechnology business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 73 staff and has a trailing 12-month revenue of around $35.6 million.

How to buy Nabriva Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – NBRV. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Nabriva Therapeutics stock price (NASDAQ: NBRV)

Use our graph to track the performance of NBRV stocks over time.

Nabriva Therapeutics shares at a glance

Information last updated 2023-02-02.
Latest market close$1.84
52-week range$1.22 - $13.50
50-day moving average $1.84
200-day moving average $3.74
Wall St. target price$1.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.92

Buy Nabriva Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Nabriva Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nabriva Therapeutics price performance over time

Historical closes compared with the close of $1.84 from 2023-02-02

1 week (2023-01-27) 22.75%
1 month (2023-01-03) -8.00%
3 months (2022-11-03) -18.76%
6 months (2022-08-03) 834.01%
1 year (2022-02-03) 310.71%
2 years (2021-02-03) -35.44%
3 years (2020-02-03) 32.37%
5 years (2018-02-02) 5.83

Nabriva Therapeutics financials

Revenue TTM $35.6 million
Gross profit TTM $3.1 million
Return on assets TTM -41.9%
Return on equity TTM -106.78%
Profit margin -133.25%
Book value $8.48
Market capitalisation $5.7 million

TTM: trailing 12 months

Nabriva Therapeutics share dividends

We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.

Have Nabriva Therapeutics's shares ever split?

Nabriva Therapeutics's shares were split on a 1:25 basis on 15 September 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.

Nabriva Therapeutics share price volatility

Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $1.215 up to $13.5. A popular way to gauge a stock's volatility is its "beta".

NBRV.US volatility(beta: 1.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.6449. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nabriva Therapeutics overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Nabriva Therapeutics is owned by insiders or institutions?
Currently 0.449% of Nabriva Therapeutics shares are held by insiders and 8.813% by institutions.
How many people work for Nabriva Therapeutics?
Latest data suggests 73 work at Nabriva Therapeutics.
When does the fiscal year end for Nabriva Therapeutics?
Nabriva Therapeutics's fiscal year ends in December.
Where is Nabriva Therapeutics based?
Nabriva Therapeutics's address is: 25-28 North Wall Quay, Dublin, Ireland, 1
What is Nabriva Therapeutics's ISIN number?
Nabriva Therapeutics's international securities identification number is: IE00BL53QQ85
What is Nabriva Therapeutics's CUSIP number?
Nabriva Therapeutics's Committee on Uniform Securities Identification Procedures number is: G63637105

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site